{"name":"Oakwood Laboratories, LLC","slug":"oakwood-laboratories-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Leuprolide Acetate for Injectable Suspension","genericName":"Leuprolide Acetate for Injectable Suspension","slug":"leuprolide-acetate-for-injectable-suspension","indication":"Advanced prostate cancer","status":"phase_3"}]}],"pipeline":[{"name":"Leuprolide Acetate for Injectable Suspension","genericName":"Leuprolide Acetate for Injectable Suspension","slug":"leuprolide-acetate-for-injectable-suspension","phase":"phase_3","mechanism":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Precocious puberty"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOU21aUVpTanJjbllnY0FYVmROWXdUa0NoZktDTjdBN2lpa09iZTIwaU5Vd29PWTkwdU5fWGZ4ZjZtYXhGUWNlWHp2Ti1XNnpZY2pTeVBodXktNlR1M1psSk52Q1diSFM5VlV0OERfc2R3V3NyLXJpS19Hbk93eElLZGV1TUJDZFFNQVZ5RHA5WE5acDRkZG1TVVpjYnNwSXBWU2o1cUJIOWxET1luS01DSUdzSElveVdMU2lBanEzZWt6MzZYVjI2SWtNN0pqZWNuT2d3VDJKQ3U1cXZs?oc=5","date":"2025-12-02","type":"pipeline","source":"TMX Newsfile","summary":"PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise - TMX Newsfile","headline":"PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOYmNZaVlNWFd3SVhUaEtKam1hTlpKMHdBUHAxQ3lQRFV1dktkMEhGemZ4VkVrUkprM0NydkxMZ0hUR3E3YUNPOUxienBIazVRVWlsQVVTbmhYQm95Skk2YXlNeTFOZ3BxQnlRWENzdDF1eHZNOVgwbUxNOFduMzJ5dG04N0hVVXdGVk9XQVNveEw2Sng4NlIxbFk5dVFjOXdTdEJxNjk1SzZVd25CNVJMZHZoQnBSQi1QTldvODZB?oc=5","date":"2025-12-02","type":"pipeline","source":"Stock Titan","summary":"PharmaTher (OTCQB: PHRRF) sells ketamine ANDA, eyes US$25 million upside - Stock Titan","headline":"PharmaTher (OTCQB: PHRRF) sells ketamine ANDA, eyes US$25 million upside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNcERrTnZ3UUxMVHBOVEZKVHpGMkRwUzhjbHdqV2oxaFdyRm1CazVsWnN0WjY0NXVpWUpLWlpCX2JnSzk3MXFOdXJTVkdUTVZrTEpCaldxXzJUNlQ5elhHb05hMUVPT25iaXFIREU4NDRGUkp0di1EMWtiUXViR1RiQXJ1UDJsSkpGQ05kSzVn?oc=5","date":"2025-11-17","type":"deal","source":"Yahoo Finance","summary":"PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program - Yahoo ","headline":"PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1mS2tsWkxpWVU0RVBHd2JpVEUtX0NVSkdHNEw0NFlkODFSczF0OVhNSWtQd191R2R6TGJOaUdpRjd2b0ZocVhoMW1oVHpxaVM3VTZ3eg?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PHRRF Stock Price, News & Analysis - Stock Titan","headline":"PHRRF Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOc0ZRVGdaYmtYVHdYZjIxR25YR0o0T3o5RHRzcHF4anc1Y0JQcElMVzhiTTU0NjlrMk5JT3hOdW9sTlNuSHVwYnRqMXVLcXhiMWxXRE13SmVtNmZZcU5WSGRESFVxTkQzYjVGSmhXRnJvSk5mY2JqRkQxdkxKREI3ekNnTmhQd0hFbVhjMmw3S2lRU1FSbUtaRTBIREdqMWNlQUlmSzJjNF8zandSMHpSR0E1OA?oc=5","date":"2021-06-30","type":"pipeline","source":"Reuters","summary":"3rd Circuit revives trade-secret claims against Aurobindo - Reuters","headline":"3rd Circuit revives trade-secret claims against Aurobindo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNdGJyMTM4ZDlOZ3NyM1dFTmkyNmNhRVgzYVpLekFtLUVscTNlU1Y4ZHZHVU5Hb1pRbk1vQXhIZEpHeWxnSTZoWUtZdkdYMTQyb0dNT0MyaGVWNVV2blNfWjZ1WmcwSVdmY2MzQTlQNUR0RzFhU3NyM2ZkZkg1MW1KeDUyVlAyS193NGhjRWMxNUk4V1VOdE8wVXBkXzdUOUVqaV9BZ2FPZ0NFeE9fbjd0NHl5U29SblFYVXFTQWRJMmEyMGdZVUo5V0hB?oc=5","date":"2021-06-22","type":"pipeline","source":"crowelltradesecretstrends.com","summary":"The Third Circuit Clarifies DTSA Pleading Requirements, While Vacating Dismissal - crowelltradesecretstrends.com","headline":"The Third Circuit Clarifies DTSA Pleading Requirements, While Vacating Dismissal","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}